NanoString revs up for U.S. launch of breast cancer prognostic Dx

NanoString Technologies ($NSTG) won a coveted 510(k) clearance for its new in vitro breast cancer diagnostic. And as it gears up for a U.S. launch, the Seattle company sees the Prosigna test as a potential game-changer, because the test kits and related hardware can be bought and run by any high-complexity CLIA lab. Typically, these types of diagnostic tests are available only at special centralized labs, Nanostring CEO Brad Gray told FierceDiagnostics. The test is based on the PAM50 gene signature and is designed to profile cells found in breast cancer tissue to assess a patient's risk of future recurrence of the disease. Story

Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,